key: cord-0712103-a0g246qp
authors: Fernández, Jorge; Bruneau, Nicole; Fasce, Rodrigo; Martín, Héctor San; Balanda, Monserrat; Bustos, Patricia; Ulloa, Soledad; Mora, Judith; Ramírez, Eugenio
title: Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies
date: 2021-09-08
journal: J Med Virol
DOI: 10.1002/jmv.27310
sha: 2fcca6884fec209de4399dcb3c5953ccd2cc08a4
doc_id: 712103
cord_uid: a0g246qp

Vaccination generates a neutralizing immune response against SARS‐CoV‐2. The genomic surveillance is showing the emergence of variants with mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we report the neutralization potency against alpha, gamma, and D614G SARS‐CoV‐2 variants in 44 individuals that received two doses of CoronaVac vaccine, an inactivated SARS‐CoV‐2 vaccine. Plasma samples collected at 60 days after the second dose of CoronaVac were analyzed by the reduction of cytopathic effect in Vero E6 cells with the three infectious variants of SARS‐CoV‐2. Plasma showed lower neutralization with alpha (geometric mean titer [GMT] = 18.5) and gamma (GMT = 10.0) variants than with D614G (GMT = 75.1) variant. Efficient neutralization against the alpha and gamma variants was not detected in 31.8% and 59.1% of plasma, respectively. These findings suggest the alpha and gamma variants could escape from neutralization by antibodies elicited by vaccination. Robust genomic and biological surveillance of viral variants could help to develop effective strategies for the control of SARS‐CoV‐2.

Several vaccines against SARS-CoV-2 have been introduced worldwide. 1 The vaccines mainly used in Chile are those developed by Sinovac and Pfizer-BioNTech; which are based on inactivated virus and lipid nanoparticles that package messenger RNA (mRNA) coding for a stabilized form of spike SARS-CoV-2 protein, respectively. 1 To date, 23,656,008 doses of vaccines have been administered in Chile: 475,168 corresponds to people with a single dose, 12,379,781 are people with first dose, and 11,276,227 people with the complete vaccination schedule. 2 The alpha (lineage B.1.1.7) and gamma (lineage P.1) variants of concern, and the lambda (lineage C.37) variant of interest are the main circulating strains in Chile. Few and preliminary information is available on the neutralization capacity of the Pfizer-BioNTech vaccine against the alpha and gamma variants. [3] [4] [5] [6] [7] If this vaccine generates neutralizing antibodies against the different SARS-CoV-2 variants has not been resolved. 3 

The positive control was a plasma from a recovered COVID-19 patient, who agreed to donate blood for plasmapheresis.

Statistical significance was determined using the two-tailed Mann-Whitney U test. p values <0.05 were considered significant.

Statistical analyses were done using Prism, version 8.0 (GraphPad Software). For the purpose of statistical analysis, a value of 5 was assigned for neutralizing antibodies titer <10 (ND). 4 Other studies suggest that this variant can evade polyclonal antibody responses, 11, 12 and has been found in cases of SARS-CoV-2 reinfection. 13 Most of the neutralization studies with mRNA vaccines have been performed with pseudoviruses, which are only able to homologate the ACE2-dependent entry step of the SARS-CoV-2 life cycle. Several studies have shown a correlation between the neutralization titers measured against pseudoviruses and live SARS-CoV-2 cultures. 14-16 However, the impact of additional mutations located outside of the spike on immune escape, virulence, infectivity, or pathogenesis has yet to be resolved.

Furthermore, it is important to point out that many studies have been conducted under different experimental conditions (e.g., replicationcapable chimeric vesicular stomatitis virus or single entry lentiviral pseudoviruses). Thus, different spike expression plasmids and combinations of mutations have also been used. All these variations with the experimental conditions do not yet make it possible to have homologous systems to measure the neutralizing antibody titers. In the present study, the neutralization potency has been measured by incubating infectious virus variants with vaccinated sera. This procedure would better mimic the real situation that would occur in vivo viral infection.

We thank Lizette Muñoz, María L. Benítez, and the technical staff of the Sección Cultivos Celulares at the Instituto de Salud Pública de Chile for the excellent technical assistance with tissue cultures. We are grateful to Agencia Nacional de Investigación y Desarrollo de Chile (ANID), which supported this study (grant no. COVID0557).

COVID-19 vaccine tracker

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021

Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Severe acute respiratory syndrome coronavirus 2 P.2 lineage associated with reinfection case, Brazil

A human monoclonal antibody blocking SARS-CoV-2 infection

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Comparison of four SARS-CoV-2 Neutralization Assays

The authors declare that there is no conflict of interests.

Jorge Fernández contributed to the study design, experimental assays, 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

http://orcid.org/0000-0003-1051-0648Eugenio Ramírez http://orcid.org/0000-0002-5299-7928